NATURE OF BUSINESS (Details) $ / shares in Units, $ in Thousands		3 Months Ended						9 Months Ended
	Jul. 31, 2023 USD ($) item $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares
Nature of Business [Line Items]
Common stock, par value per share | $ / shares		$ 0.0001						$ 0.0001		$ 0.0001
Net income (loss)		$ (82,631)	$ (72,956)	$ (82,551)	$ (85,092)	$ (82,546)	$ 20,726	$ (238,138)	$ (146,912)
Cash, Cash Equivalents, and Short-term Investments		1,200,000						1,200,000
Accumulated deficit		$ (765,727)						(765,727)		$ (527,589)
Amount of non cash income (loss) from contingent earn out liability and warrant liability								$ 9,100	$ 95,800
EQRx, Inc | Revolution Medicines, Inc
Nature of Business [Line Items]
Common stock, par value per share | $ / shares	$ 0.0001
Shares issued in business combination | shares	7,692,308
Value of equity Interest Issued or Issuable	$ 200,000
Share Price | $ / shares	$ 26.00
Value of additional equity interest issued or issuable	$ 870,000
Number of trading days | item	5
Percentage of discount applied on additional number of shares issued or issuable	6.00%
Percentage of common stock subject to Warrants considered for determination of Exchange Ratio	10.00%
Percentage of common stock subject to earn-out shares considered for determination of Exchange Ratio	10.00%